Cxbladder is a non-invasive genomic urine test designed to detect or rule out bladder cancer in haematuria patients, and those being monitored for bladder recurrence following treatment.
- Accurate rule out, reducing the need for further invasive procedures
- Resolve atypical cytology and equivocal cystoscopy
- Improve overall detection accuracy
Cxbladder works at a molecular level. The test combines clinical risk factor markers with genetic information, measuring five biomarker genes to detect the presence or absence of bladder cancer.
- Reliable: Cxbladder utilises high sensitivity and negative predictive value to either help rule out the disease or complement other diagnostic procedures and tests to improve overall detection accuracy.
- Clinically proven: Proven performance in more than 20 peer-reviewed publications for rule out, primary detection, and surveillance. 70% of the New Zealand population now have access to Cxbladder via public healthcare, with more DHBs expected to follow soon.
- Easy-to-use: Cxbladder’s unique urine sample collection system is discrete, non-invasive and easy-to-use, taking only minutes.
- In-home sampling: To streamline patient care we are now offering an in-home sampling service to both haematuria and surveillance patients.
- Quick: Upon receiving a urine sample, our certified NZ laboratory will provide actionable results in 5 days.
A Suite of Tests Optimised to Primary Detection and Surveillance
Cxbladder is a suite of tests each optimised for a specific point along the patient journey.
Designed for patients presenting with haematuria. Cxbladder Triage analyses the presence of five biomarker genes alongside information on known bladder cancer risk factors like age, gender and smoking history to rule out patients with a low risk of having the disease.
Cxbladder Triage provides accurate results and reassurance that can reduce the need for further invasive procedures.
In cases where a patient is symptomatic and bladder cancer looks likely, Cxbladder Detect can help confirm your diagnosis.
By detecting and quantifying signs of cancer at the molecular level, Cxbladder Detect outperforms other urine-based tests, making it an ideal choice for bladder cancer testing when patients present with significant symptoms. Cxbladder Detect can be used as an adjunct to cystoscopy or as a substitute for other radiological tests to improve overall detection accuracy. The test can also provide certainty when other procedures and tests are inconclusive. Cxbladder Detect is proven to adjudicate atypical cytology and equivocal cystoscopy.
Developed specifically for patients undergoing surveillance for recurrent bladder cancer. The test combines clinical information linked to previous bladder cancer with measured biomarker genes to help rule out the presence of a recurrent tumour, or to indicate that further clinical investigation is required.
Cxbladder Monitor can provide accurate results with a single urine sample, and test is often used as a non-invasive monitoring alternative to reduce the need for frequent cystoscopies.
Request More Info on Triage, Detect or Monitor
Featured study: Chu C, Li K, Meng M, Porten S. PD63-12: Use of Cxbladder Monitor during the COVID-19 Pandemic to reduce the frequency of surveillance cystoscopy. J Urol 2021; 206(3):1142e [abstract available]
Grand Rounds in Urology: Panel Discussion on Cxbladder Genomic Urine Test for Bladder Cancer. May, 2021. Sia Daneshmand, MD (Keck School of Medicine, USC), leads discussion with Sima Porten, MD (UCSF), and Anne Schuckman, MD (USC).
Cxbladder In-Home Sampling is Available
Cxbladder’s unique urine sampling system is non-invasive and easy-to-use. The process is quick and painless, taking only minutes.
To simplify and streamline the bladder cancer testing process, we are now offering in-home sampling for patients around the country. Patients have the option of submitting their Cxbladder urine sample in the comfort of their own home without the need to physically visit a clinic.
The Difference in Cancer Detection
Cxbladder is a reliable test for bladder cancer that can help you make informed treatment and care decisions.
Most symptomatic or surveillance patients do not have bladder cancer. Cxbladder enables the accurate rule out of patients with haematuria and those being monitored for recurrence, reducing the burden of cystoscopy and sparing patients anxiety and discomfort. The test also solves a diagnostic dilemma, accurately resolving atypical cytology and equivocal cystoscopy in the evaluation of patients presenting with haematuria or being monitored for recurrence.
Contact Us to Request More Information
Last Updated: 04 Aug 2022 10:56 am
Pacific Edge is responsible for the development and determination of the performance characteristics for Cxbladder. Because Cxbladder is a Laboratory Developed Test (LDT), Cxbladder has not been cleared or approved by the US Food and Drug Administration (FDA).
Browse Our Latest Blog Articles
Diagnosing bladder cancer
Dr Rod Studd discusses the guidelines, issues and technologies for diagnosing UC in patients presenting with hematuria in primary care.
Comprehensive solution for your clinical needs
Cxbladder gives you actionable results that can make a meaningful difference in your patient’s diagnosis and treatment.Learn more about Cxbladder’s clinical applications
Cxbladder sampling process
Cxbladder is a suite of non-invasive tests that is easy and straightforward to use.Watch the instructional video here
Talk to a Rep
Contact us by phone or email, or fill out an online form and a Cxbladder representative will get back to you.Complete an information request form today